In addition to being used in numerous oncology clinical trials, saracatinib has been explored as a FYN kinase inhibitor in a phase II study of patients with mild-to-moderate Alzheimer’s disease at doses up to 125 mg daily for 12 months (4, 39, 40) (NCT02167256). This evidence concerns the gene FYN and early-onset autosomal dominant Alzheimer disease.